Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study - Garcia-Manero, G; Daver, N; Xu, J; Chao, M; Chung, T; Tan, A; Wang, Y; Wei, A; Vyas, P; Sallman, D (Elsevier, 2021)